AR118729A1 - Inhibidor selectivo de la jak1 quinasa - Google Patents
Inhibidor selectivo de la jak1 quinasaInfo
- Publication number
- AR118729A1 AR118729A1 ARP200101101A ARP200101101A AR118729A1 AR 118729 A1 AR118729 A1 AR 118729A1 AR P200101101 A ARP200101101 A AR P200101101A AR P200101101 A ARP200101101 A AR P200101101A AR 118729 A1 AR118729 A1 AR 118729A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- alkoxy
- nrarb
- hydroxyl
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- -1 hydroxy, amino Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 229910003827 NRaRb Inorganic materials 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083376 | 2019-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118729A1 true AR118729A1 (es) | 2021-10-27 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101101A AR118729A1 (es) | 2019-04-19 | 2020-04-17 | Inhibidor selectivo de la jak1 quinasa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220220096A1 (enExample) |
| EP (1) | EP3956322B1 (enExample) |
| JP (1) | JP7555959B2 (enExample) |
| KR (1) | KR20220003537A (enExample) |
| CN (1) | CN113710664B (enExample) |
| AR (1) | AR118729A1 (enExample) |
| AU (1) | AU2020258619B2 (enExample) |
| BR (1) | BR112021020964A2 (enExample) |
| CA (1) | CA3134174A1 (enExample) |
| DK (1) | DK3956322T3 (enExample) |
| ES (1) | ES3031576T3 (enExample) |
| MX (1) | MX2021012749A (enExample) |
| PT (1) | PT3956322T (enExample) |
| TW (1) | TW202104215A (enExample) |
| WO (1) | WO2020211839A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7613778B2 (ja) * | 2020-11-26 | 2025-01-15 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) * | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| HRP20230069T1 (hr) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Selektivni inhibitori jak1 |
| WO2020057669A1 (zh) * | 2018-09-21 | 2020-03-26 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
-
2020
- 2020-04-17 TW TW109112994A patent/TW202104215A/zh unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619B2/en active Active
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 US US17/604,442 patent/US20220220096A1/en active Pending
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES3031576T3 (en) | 2025-07-09 |
| EP3956322A1 (en) | 2022-02-23 |
| US20220220096A1 (en) | 2022-07-14 |
| PT3956322T (pt) | 2025-06-04 |
| EP3956322B1 (en) | 2025-05-14 |
| KR20220003537A (ko) | 2022-01-10 |
| WO2020211839A1 (en) | 2020-10-22 |
| BR112021020964A2 (pt) | 2021-12-14 |
| JP2022529061A (ja) | 2022-06-16 |
| CA3134174A1 (en) | 2020-10-22 |
| CN113710664A (zh) | 2021-11-26 |
| TW202104215A (zh) | 2021-02-01 |
| DK3956322T3 (da) | 2025-06-16 |
| JP7555959B2 (ja) | 2024-09-25 |
| AU2020258619B2 (en) | 2025-10-23 |
| MX2021012749A (es) | 2021-11-18 |
| CN113710664B (zh) | 2024-01-26 |
| EP3956322A4 (en) | 2023-05-03 |
| AU2020258619A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118729A1 (es) | Inhibidor selectivo de la jak1 quinasa | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| ECSP22022958A (es) | Moduladores poliheterociclicos de sting (estimulador de genes de interferón) | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
| SV2016005351A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| PE20160044A1 (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| AR110088A1 (es) | Inhibidores de magl | |
| MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| CO2022008719A2 (es) | Compuestos para modular la actividad de fxr y usos de los mismos | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
| AR089853A1 (es) | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| PE20212333A1 (es) | Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento |